1.250EURMkt Cap: 37.02M EURP/E: —Last update: 2026-05-21
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap37.02M EUR
Enterprise Value31.36M EUR
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.85M EUR
Revenue/Share—
Last Price1.250 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees13
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINNL00150002Q7
Valuation
P/E (Trailing)—
P/E (Forward)-3.38
PEG—
EV/EBITDA-3.55
EV/Revenue—
P/S—
P/B10.33
EPS (TTM)-0.33
EPS (Forward)-0.37
52W Range
1.24520% of range1.270
52W High1.270 EUR
52W Low1.245 EUR
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-187.29%
ROA-117.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.46M EUR
CapEx (TTM)6.00K EUR
FCF Margin—
FCF Yield-11.73%
Net Debt-5.51M EUR
Net Debt/EBITDA0.62
Balance Sheet
Debt/Equity0.02
Current Ratio7.68
Quick Ratio7.20
Book Value/Sh0.1210 EUR
Cash/Share0.1900 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.500 EUR
Target Range7.500 EUR – 7.500 EUR
# Analysts1
Ownership
Shares Out.29.61M
Float25.32M
Insiders21.45%
Institutions8.90%
Technical
SMA 501.309 (-4.5%)
SMA 2001.491 (-16.2%)
Beta1.38
S&P 52W Chg27.23%
Avg Vol (30d)42.27K
Avg Vol (10d)30.11K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—